ALLO — Allogene Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $336.76m
- $44.28m
- $0.02m
Annual income statement for Allogene Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 114 | 0.156 | 0.095 | 0.022 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 258 | 294 | 336 | 328 | 273 |
| Operating Profit | -258 | -180 | -336 | -328 | -273 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -250 | -182 | -340 | -327 | -257 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -250 | -182 | -340 | -327 | -258 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -250 | -182 | -340 | -327 | -258 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -250 | -182 | -340 | -327 | -258 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.08 | -1.34 | -2.38 | -2 | -1.26 |